BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ueno T, Ishida T, Aluri J, Suzuki M, Beuckmann CT, Kameyama T, Asakura S, Kusano K. Disposition and Metabolism of [ 14 C]Lemborexant in Healthy Human Subjects and Characterization of Its Circulating Metabolites. Drug Metab Dispos 2020;49:31-8. [DOI: 10.1124/dmd.120.000229] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Landry I, Aluri J, Hall N, Filippov G, Dayal S, Moline M, Reyderman L. Effects of Lemborexant on the Pharmacokinetics of Oral Contraceptives: Results From a Phase 1 Drug-Drug Interaction Study in Healthy Females. Clin Pharmacol Drug Dev 2021;10:1089-98. [PMID: 34107159 DOI: 10.1002/cpdd.953] [Reference Citation Analysis]
2 Ueno T, Miyajima Y, Landry I, Lalovic B, Schuck E. Physiologically-based pharmacokinetic modeling to predict drug interactions of lemborexant with CYP3A inhibitors. CPT Pharmacometrics Syst Pharmacol 2021;10:455-66. [PMID: 33704920 DOI: 10.1002/psp4.12606] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Landry I, Aluri J, Hall N, Filippov G, Dayal S, Moline M, Reyderman L. Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant. Pharmacol Res Perspect 2021;9:e00734. [PMID: 33689224 DOI: 10.1002/prp2.734] [Reference Citation Analysis]
4 Asakura S, Shiotani M, Gauvin DV, Fujiwara A, Ueno T, Bower N, Beuckmann CT, Moline M. Nonclinical evaluation of abuse liability of the dual orexin receptor antagonist lemborexant. Regul Toxicol Pharmacol 2021;127:105053. [PMID: 34619288 DOI: 10.1016/j.yrtph.2021.105053] [Reference Citation Analysis]
5 Dayal S, Aluri J, Hall N, Filippov G, Moline M, Reyderman L, Landry I. Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant. Pharmacol Res Perspect 2021;9:e00758. [PMID: 33822479 DOI: 10.1002/prp2.758] [Reference Citation Analysis]